ANti-tick vaccines to prevent TIck-borne Diseases in Europe.
ANTIDotE is a consortium of 7 European research institutes funded by the European Commssion to investigate anti-tick vaccines. Our objective is to identify and characterize tick salivary gland proteins involved in tick feeding and tick-borne pathogen transmission, and to use this knowledge to develop and assess anti-tick vaccines to prevent multiple human tick-borne diseases.
Workshop: Antidote’s for tick borne diseases, 3rd of June 2016 in Berlin
Aim of the workshop is to bring together key stakeholders to identify and explore strategic steps that need to be taken for successful implementation of anti-tick vaccines in health systems in Europe.
The ANTIDotE consortium consists of 7 European participants, and an advisory board with 7 partners with different backgrounds and networks. This enables ANTIDotE to achieve its groundbreaking objectives.
For more information on the participants see the participants section of this website. The advisory board consists of Yale University (Yale), the Research Institite for Wildlife Health in Europe (Artemis), the Friedrich-Loeffler Institute (FLI), the National Institute of Public Health from the Czech Republic (NIPH CZ), Nationa Public Health Institute of Slovenia (NPHI SL), Center for Tick-borne Diseases in Hungary (CTB) and Theo Schetters (current protActivity and former Merck, Sharp & Dohme (MSD).